Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti …

Get live updates on this topic:
Silent notifications:
Interval of time threshold:
Get live updates on this topic:
Silent notifications:
Interval of time threshold:
We will only send you breaking news updates, and your own specified custom filters notifications.